Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

r licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2006 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization, including Old Stressgen's 2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and ATLANTA , August 28, 2015 ... Food and Drug Administration (FDA) cleared the MagVita TMS Therapy ... patients who have failed to receive satisfactory improvement from prior ... technique for stimulating neural tissue in the part of the ... procedure has been proven safe and effective and MagVenture is ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... STEWARTVILLE, Minn., Sept. 12 Rochester,Medical Corporation ... publication of,results from a significant clinical study ... proprietary Infection Control Technology. The newly ... Internal Medicine",presents results of a randomized, double-blind, ...
... Include 1,000 mg Dose, PRINCETON, N.J., Sept. 12 ... discovery and development of novel,small molecule therapeutics, today announced ... multiple ascending dose (MAD) study of its lead,internal product ... with any of the doses under evaluation. As a ...
Cached Medicine Technology:Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial 2Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial 3Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 2Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 3Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 4
(Date:8/29/2015)... ... August 29, 2015 , ... People who have ... (including emphysema), or asthma, are at higher risk from wildfire smoke especially in ... failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of the stage ... short segment to the subject of diabetes. Diabetes is a debilitating health condition that ... recent advancements in medical science may prove to be a significant breakthrough that sufferers ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
(Date:8/28/2015)... Las Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... is announcing its decision to make the purchase of CPAP equipment more affordable by ... This offer includes all types of CPAP products and orders of any size. My ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... The percentage of physicians who provide free care to ... this is fast becoming huge problem for America’s quickly ... to a study conducted by the Center for Studying ... physicians provided charity care in the mid-1990s, compared with ...
... Institute of Technology has developed a new multi-functional sensing ... role in cystic fibrosis. // ,This ... tip of an atomic force microscope (AFM), creating a ... electrochemical activity at the cell surface. , ...
... Prolacta Bioscience, a for-profit company, started marketing a breast-milk concentrate ... their own milk on the Internet for $1 to $2.50 ... regulation and raise a lot of ethical and safety questions. ... at Presbyterian/St. Luke’s Medical Center said that this might affect ...
... well aware of Kawasaki as a motorcycle rather than a ... informed that his 9 year old daughter, Utkarsha was suffering ... as it is prevalent among Korean and Japanese children. 'I ... Kawasaki was a disease,' remarked Dinesh Ghai. ,Kawasaki ...
... found that babies born to women, who are hospitalized for ... APGAR scores and are more likely to be put under ... number of previous pregnancies, smoke more heavily and are less ... the April issue of Alcoholism: Clinical and Experimental Research. ...
... offer a pay of nearly $500,000 to the head of ... proposal, the Queensland Opposition has described it as being extravagant ... advertised for the post of a new director for the ... $500,000-plus. This is believed to pave way for enormous ...
Cached Medicine News:Health News:Fewer Doctors Treating For Free 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Mama’s milk on sal 2Health News:Low Awareness Of Kawasaki Disease In Capital: Parents Form Support Group 2Health News:Use Of Alcohol During Pregnancy Affects Newborns 2
... laryngoscope handles can be used with Portex® ... sturdy chrome blades with long-lasting bronze fiber-optic ... for continuous routine use., ,The laryngoscope ... of sizes, from infant to large adult, ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
... Articulating Tip Laryngoscopes are the ... Industry. The articulating tip aids ... an improved view of epiglottis. ... Optic styles. We guarantee your ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: